SRNE News and Press, Sorrento Therapeutics Inc. From 03/24/22

FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group –  Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight back with other than more restrictions or ...

Sorrento scientists have perfected the expression of the spike protein to potentially improve the safety profile of the COVID-19 mRNA vaccines by incorporating a furin cleavage site mutation to prevent leakage of S1 subunit into the blood circulation targeting vital organ tissues with ACE...

The shares of biotech Sorrento Therapeutics (NASDAQ: SRNE) ended the week on a high note, rising a bit over 1% on Friday. The catalyst was some encouraging clinical news from a subsidiary. Sorrento announced on Friday morning that Scilex Holding, a business that it has a majorit...

Sorrento Therapeutics (NASDAQ:SRNE) subsidiary Scilex's SP-102 (Semdex), a candidate for sciatica pain management, demonstrated rapid onset of pain relief in a late-stage trial. Four weeks after a single injection, patients taking SP-102 demonstrated a statistically significant mean improveme...

SP-102 (SEMDEXA™), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy), experienced a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily pain in the affected leg, with highly statistical...

Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140 million in expected gross proceeds before expenses, assuming no redemptions from Vickers Vantage Corp. I’s existing public shar...

Sorrento Therapeutics' revenues are up 33% year-on-year. The Company recently received orders for its COVISTIX. Sorrento Therapeutics has acquired Fortune Bioscience and Virex Health. For further details see: Sorrento Therapeutics: Sales Are Up But EY Identifies Internal...

San Diego, California-based biotech Sorrento Therapeutics (SRNE +1.2%) announced on Wednesday that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application (IND) for intranasal STI-9199 (COVISHIELD), an experimental antibody against COVID-19. The company pl...

STI-9199 neutralizing antibody (nAb) nasal drops prevent productive infections when given to animals 24 hours before they are exposed to COVID. This intranasal STI-9199 may potentially give the option to take a dose of STI-9199 to prevent spread of infection within a home and to all...

FDA granted IND clearance today for STI-9199 (COVISHIELD ™ ) for a Phase 1 safety and pharmacokinetic study in healthy volunteers. Initial trials are expected to be followed by a multinational Phase 2/3 trial in both mild and moderate COVID-19 patients. STI-9199 has d...